^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OncoFOLLOW

    Company:
    OncoDNA
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    9ms
    CSFctDNA as a surrogate for tumor tissue DNA in BC pts with CNS metastases: First results from the Brainstorm program (Oncodistinct 006) (AACR 2024)
    The use of CSFctDNA as a surrogate for tumor tissue DNA in CNS metastases appears to be a feasible and safe approach. Clinically actionable alterations have been identified in CSFctDNA of pts with BC. Further results will be presented at a later stage.Table 1: Pathogenic molecular alterations in matched tumor, plasma and CSF from pts with detectable CSFctDNA
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    OncoDEEP • OncoFOLLOW
    over1year
    Serial cell-free tumor DNA in prognosing survival in patients with head and neck squamous cell carcinoma treated with upfront surgery (ESMO 2023)
    Conclusions Serial ctDNA analyses at surgery and in the postoperative setting had a strong prognostic value. Early detection of ctDNA after surgery might be of interest to stratify HNSCC patients for adjuvant therapy when treated with upfront surgery.
    Clinical • Surgery • Circulating tumor DNA
    |
    OncoFOLLOW
    over1year
    Spatial and longitudinal tumor heterogeneity in head and neck squamous cell carcinoma patients treated with primary surgery (AACR 2023)
    Our study suggests spatial and longitudinal tumor heterogeneity and reports emerging mutations in ctDNA over time in HNSCC. Prognostic significance characterization of the ctDNA dominant clone allele frequency is ongoing.
    Clinical • Surgery
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • NOTCH1 (Notch 1) • JAK2 (Janus kinase 2) • FAT1 (FAT atypical cadherin 1) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A)
    |
    TP53 mutation • KRAS mutation • PIK3CA mutation • TP53 mutation + KRAS mutation • KRAS mutation + TP53 mutation
    |
    OncoFOLLOW
    almost3years
    OncoDNA and Bergonié Institute to test the clinical utility of blood-and tissue-based biomarker tests in oncology (OncoDNA Press Release)
    "OncoDNA...and Bergonié Institute...announced a new clinical trial to evaluate the use of comprehensive biomarker testing and liquid biopsy in 700 patients diagnosed with an advanced metastatic cancer. The Appolo study will recruit patients from 6 participating sites across the French Aquitaine region to be offered OncoDEEP® and OncoFOLLOW™ biomarker tests."
    New trial
    |
    OncoDEEP • OncoFOLLOW